Related Experiment Video
Updated: Jan 12, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Decline in pediatric respiratory syncytial virus hospitalizations following nirsevimab implementation: A multicenter,
Anna Creus-Costa1, Cristina Andrés2, Jorgina Vila3
1Pediatric Hospitalization Unit, Hospital Infantil i de la Dona Vall d'Hebron, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain; Infection and Immunity in Pediatric Patients Research Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain; Universitat Autònoma de Barcelona, Bellaterra, Catalonia, Spain.
Objectives:
To describe the demographic characteristics and clinical outcomes of hospitalized children with RSV in Catalonia during the first two seasons after the implementation of nirsevimab compared to the preceding season.
Methods:
This observational study included patients <18 years hospitalized across 12 Catalan hospitals during three RSV seasons: 2022-2023, 2023-2024, and 2024-2025. We collected demographic, clinical and microbiological data on patients with a laboratory-confirmed RSV-positive respiratory sample.
Results:
RSV-associated hospitalizations among <6-month-olds declined by 66.7% and 77.6% in the 2023-2024 and 2024-2025 seasons, respectively, compared to the prenirsevimab season. This resulted in overall reductions of 40.8% and 28.4% across all age groups and an increase in patient median age (16.6 and 11.8 vs 4.8 months, P < 0.001). PICU admissions for under 6-month-olds decreased by 69.8% and 75.5%, with global declines of 49.2% and 44.1%. There was a slight rebound in hospitalizations in 2024-2025. Median hospital length of stay and respiratory support duration both decreased by one day between 2022-2023 and 2024-2025. The proportion of patients with preexisting conditions such as asthma increased significantly (32.1% and 38.6% vs 19.7%, P < 0.001).
Conclusions:
After implementing nirsevimab, there was a significant decrease in pediatric RSV-associated hospitalizations and PICU admissions, especially among under 6-month-olds. The increase in patient median age and preexisting conditions highlight the need for new preventive strategies for these at-risk groups.
Related Concept Videos
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Acute Respiratory Failure-III
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...

